WO2012107541A1 - Composition pharmaceutique comprenant du tadalafil et une cyclodextrine - Google Patents

Composition pharmaceutique comprenant du tadalafil et une cyclodextrine Download PDF

Info

Publication number
WO2012107541A1
WO2012107541A1 PCT/EP2012/052266 EP2012052266W WO2012107541A1 WO 2012107541 A1 WO2012107541 A1 WO 2012107541A1 EP 2012052266 W EP2012052266 W EP 2012052266W WO 2012107541 A1 WO2012107541 A1 WO 2012107541A1
Authority
WO
WIPO (PCT)
Prior art keywords
tadalafil
granulate
cyclodextrin
beta
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/052266
Other languages
English (en)
Inventor
Marta VIVANCOS MARTINEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/051969 external-priority patent/WO2012107092A1/fr
Application filed by Synthon BV filed Critical Synthon BV
Priority to RU2013141446/15A priority Critical patent/RU2013141446A/ru
Priority to EP12704054.1A priority patent/EP2672960A1/fr
Publication of WO2012107541A1 publication Critical patent/WO2012107541A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a co- granulate of tadalafil and beta-cyclodextrin as the main components.
  • CIALIS® is a known pharmaceutically active compound, which is marketed, e.g., under brand name CIALIS®, for treatment of erectile dysfunction and pulmonary arterial hypertension.
  • the marketed product is a film-coated tablet for oral administration comprising 2.5, 5, 10 or 20 mg of the active substance.
  • Inactive ingredients in CIALIS® are lactose monohydrate, croscarmellose sodium, hydroxypropylcellulose, microcrystalline cellulose, sodium laurylsulfate and magnesium stearate.
  • Tadalafil and its pharmaceutical compositions have been disclosed, e.g., in
  • tadalafil is in a certain aspect a follow-up product to the well known compound sildenafil (Viagra). Its main advantage is longer duration of action and minimized potential for side effects such as vision abnormalities.
  • tadalafil is thereby finely dispersed in the carrier, which may result in improved dissolution due to the enhanced surface area of the drug substance.
  • solid dispersions comprising tadalafil have been disclosed, e.g., in WO 96/38131.
  • Molecular dispersions of tadalafil in a polymeric carrier have been disclosed, e.g., in WO 2009/000493.
  • An adsorbate of tadalafil on the surface of silica has been disclosed in EP 2238979.
  • Still another possibility of improving the dissolution rate of tadalafil from solid dosage forms is to formulate it into quickly disintegrating sublingual dosage forms.
  • Examples of such compositions have been disclosed, e.g., in WO 00/20033, WO 01/41807,
  • the present invention relates to pharmaceutical compositions comprising a co-granulate of tadalafil with a cyclodextrin as the pharmaceutically active component.
  • the present invention provides a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising a co-granulate of tadalafil with beta-cyclodextrin, in a molar ratio higher than 1:1, typically a molar ratio of about 1:1.25, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, and at least one pharmaceutically acceptable excipient.
  • the tadalafil starting material comprises a population of tadalafil particles characterized by a particle size d(0.9) >40 microns.
  • the invention provides a compressed dosage form, which typically is a tablet for oral administration of tadalafil, comprising the dose amount of the above defined composition.
  • the tablet comprises from 1 to 50 mg of tadalafil.
  • the dosage form exhibits a dissolution rate of at least about 75 wt% within about 15 min when tested by Ph.Eur. paddle method in 1000 ml of aqueous medium containing 0.35% of SLS with paddle rotating at a speed of 50 rpm.
  • the invention provides a co-granulate of tadalafil with beta- cyclodextrin, in molar ratio higher than 1:1, typically a molar ratio of about 1:1.25, 1: 1.3, 1:1.5, 1:2, 1:2.5, 1:3, in a free flowing particulate form.
  • the invention provides a process of making a co-granulate of tadalafil with beta-cyclodextrin in a free flowing particulate form comprising
  • the above process steps are followed by the next step of formulating the produced co-granulate into a solid pharmaceutical composition and/or into a solid dosage form for oral administration, e.g. to compressed dosage form, which typically is a tablet.
  • the formulation step into the tablet comprises direct compression.
  • the invention relates to use of co-granulate of tadalafil with beta- cyclodextrin, in a molar ratio higher than 1:1, typically a molar ratio of about 1:1.25, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, and preferably in a free flowing particulate form, in medicine, particularly in combination with a disintegrant.
  • the present invention relates to a discovery that a complex of tadalafil with beta- cyclodextrin may be prepared by a simple and reliable process and in a form, which is well suitable for formulation into solid pharmaceutical compositions and for making tablets for oral administration of tadalafil.
  • Cyclodextrins are compounds made up of sugar molecules bound together in a ring and are composed of 5 or more a-D-glucopyranoside units linked l->4. Cyclodextrins are produced from starch by means of enzymatic conversion. Three naturally occurred cyclodextrins are known, one of these three, the so-called beta-cyclodextrin, has seven sugar molecules in the ring. As the natural beta-cyclodextrin exhibits relatively low aqueous solubility, various semi synthetic derivatives with enhanced aqueous solubility have been developed.
  • 2-hydroxy-propyl-beta-cyclodextrin (2-HPCD), which is a partially substituted poly(2-hydroxpropyl) ether of beta-cyclodextrin. Its aqueous solubility is quite high, exceeding 600 mg/ml.
  • Cyclodextrins may form stable complexes with various chemicals, in which the molecule of the chemical is encapsulated inside the cyclodextrin ring and forms a so called inclusion complex. Thereby, original properties of the chemical vis-a-vis the cyclodextrin- complexed chemical may be modified (For more details, see e.g., Arthur H. Kibbe (Ed.), Handbook of Pharmaceutical Excipients, Third Edition 2000, p. 165-168).
  • the present invention provides a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising a co- granulate of tadalafil with beta-cyclodextrin, in a molar ratio higher than 1: 1, typically of molar ratio of about 1: 1.25, 1: 1.3, 1: 1.5, 1:2, 1: 2.5, 1 :3, and at least one pharmaceutically acceptable excipient.
  • Formulation of the tadalafil and beta-cyclodextrin in a form of a co-granulate is advantageous as it avoids using complicated and expensive freeze-drying.
  • the co-granulation assures a proper degree of complexation of tadalafil, which may be demonstrated by the fact that the co-granulate exhibits better dissolution rates than a plain physical mixture of both components.
  • the co-granulate may be obtained as a free flowing particulate product, which is an advantageous form because it is well manageable in the process of formulating pharmaceutical compositions.
  • composition of the present invention is a result of comparative study of the behaviour of tadalafil in solid granulated compositions comprising various cyclodextrins in the presence of pharmaceutically acceptable extragranular fillers, diluents and disintegrants, for instance in the presence of excipients found in Cialis. Contrary to the expectations predicted by Badr-Eldin et al., it was a co-granulate with natural beta-cyclodextrin, which provided the fastest dissolution of tadalafil when tested in an aqueous environment comprising 0.35% sodium lauryl sulfate (SLS), by a Ph.Eur. paddle method. Quite surprisingly, the high aqueous solubility of semi-synthetic cyclodextrins such as
  • hydroxypropyl-beta-cyclodextrin is apparently not essential for making tadalafil-comprising solid pharmaceutical compositions with a good dissolution, e.g. with a dissolution comparable to Cialis tablets.
  • the inventor speculates that the presence of certain excipients in the solid composition, apparently mainly disintegrants, also contributes to the overall dissolution rate; when combining this contribution with an effective complexation of the tadalafil by beta-cyclodextrin, a proper synergy is obtained.
  • beta-cyclodextrin may be successfully used in this particular case.
  • an optimal molar ratio is higher than 1:1, and preferably is about 1: 1.25, 1:1.3, 1: 1.5, 1:2, 1:2.5, 1:3.
  • Compositions comprising the tadalafil-beta-cyclodextrin co-granulate of molar ratio lower that 1 : 1 exhibited an undesirably slow dissolution rate, probably due to less complexation.
  • Higher absolute amounts of beta-cyclodextrin in final compositions e.g.
  • the tadalafil-beta-cyclodextrin co-granulate is formulated into a tablet composition, due to a lack of flowability.
  • the molar ratio between tadalafil and beta-cyclodextrin should not exceed 1:8, preferably not exceed 1:5.
  • the total amount of beta- cyclodextrin in a single tablet made from the co-granulate does not exceed 150 mg, preferably does not exceed 75 mg.
  • a useful process of making the co-granulate of tadalafil and beta-cyclodextrin in a free- flowing particulate form comprises the following steps:
  • beta-cyclodextrin wetting, under stirring, beta-cyclodextrin with 5 to 30%, preferably with 10 to 25% and most preferably with about 20% of water (w/w).
  • the mixing and homogenization is typically performed in the same equipment, at a speed of about 100 to 200 rpm.
  • the time of mixing plays a certain role as a well
  • the drying step is performed in fluid bed equipment, at a temperature of about 40°C to about 50°C.
  • the dry co-granulate may be milled and/or sieved on a suitable equipment.
  • the co-granulate may also comprise some auxiliary intra- granulate excipients.
  • it may also comprise a suitable solubilizer.
  • solubilizer may enhance the effect of cyclodextrin and/or may save the overall amount of the relatively expensive cyclodextrin.
  • the examples of solubilizers are, without limitation, hydroxypropylmethyl cellulose, polyethylene glycol (PEG 4000, PEG 6000),
  • the co-granulate may also comprise an intragranular disintegrant, e.g. a crosscarmellose sodium or crospovidone.
  • the amount of a disintegrant in the co-granulate is advantageously less than 10%,
  • the co-granulate may comprise a suitable binder/diluent such as microcrystalline cellulose or lactose.
  • the auxiliary excipients may be incorporated into the granulate both in the wetting and in the mixing / homogenization step.
  • the process of making the co-granulate comprises the following steps:
  • beta-cyclodextrin wetting, under stirring, beta-cyclodextrin with 5 to 30%, preferably with 10 to 25% and most preferably with about 20% of water (w/w), wherein the water contains dissolved solubilizer, e.g. PEG 4000, optionally in the presence of binder/diluent and/ or disintegrant.
  • solubilizer e.g. PEG 4000
  • beta-cyclodextrin ration molar ratio higher than 1:1 typically of molar ratio of about 1:1.25, 1:1.3, 1:1.5, 1:2, 1:2.5, 1:3, and homogenizing the mixture by stirring for at least 30 minutes, typically from 2 to 5 hours.
  • the dry co-granulate may be milled and/or sieved on a suitable equipment.
  • the process comprises the following steps:
  • beta-cyclodextrin wetting, under stirring, beta-cyclodextrin with 5 to 30%, preferably with 10 to 25% and most preferably with about 20% of water (w/w), wherein the water contains dissolved solubilizer, e.g. PEG 4000, optionally in the presence of binder/diluent.
  • solubilizer e.g. PEG 4000
  • the dry co-granulate may be milled and/or sieved on a suitable equipment.
  • the co-granulate of the present invention may be formulated into well dissoluble solid pharmaceutical compositions without a requirement that the starting tadalafil must be of a small particle size. Specifically, it is not necessary to provide a population of tadalafil particles of an particles size (when expressed by the d(0.9) value) of less than 40 micrometers. Instead, it is possible and in certain aspects advantageous, to use batches of tadalafil having the average particle size d(0.9) higher than 40 micrometers, e.g. tadalafil directly produced by a chemical synthesis.
  • the "d(0.9) " in an association with a number means that the size of 90% of particles of the population is less than or equal to the size expressed by that number when measured by a light scattering method.
  • the co-granulate of the present invention may be formulated into solid pharmaceutical compositions, preferably to tablet compositions, by combining it, typically by dry mixing or by wet granulation/mixing, with at least one extragranular pharmaceutical excipient.
  • the composition typically does not comprise any excipient serving as a release-controlling agent.
  • the at least one extragranular excipient(s) may be selected from
  • At least one disintegrant are, without any limitation, starches, modified celluloses or crosslinked polymers such as starch, modified starch, croscarmellose sodium, carboxymethylcellulose calcium, crospovidone, sodium starch glycolate, polacrilin potassium, sodium alginate, guar gum, etc.
  • a preferred disintegrant is croscarmellose sodium.
  • the extragranular disintegrant is an important excipient. As discussed above, it appears that the disintegrant potentiates the effect of the cyclodextrin and improves the overall release rate. Preferred amount of the disintegrant is from 1 to 5 weight %, based on the total mass of the composition. In some embodiments, the final composition may comprise both an extragranular disintegrant and an intragranular disintegrant, which may be the same or different.
  • At least one water soluble or water insoluble filler /binder At least one water soluble or water insoluble filler /binder.
  • the examples are, without any limitation, lactose, lactose monohydrate, mannitol, sorbitol,
  • microcrystalline cellulose methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, dextrose, fructose, lactitol, maltitol, maltodextrins, maltose, calcium phosphates, xylitol, starch, modified starch, polyvinylpyrrolidone, copovidone, sodium alginate, etc.
  • At least one solubilizer At least one solubilizer.
  • the examples are, without any limitation, hydroxypropyl methylcellulose, polyvinylpyrrolidone, nicotinamide, polyoxyethylene (20) sorbitan monooleate (Tween 80), polyethylene glycol (PEG 4000), sodium lauryl sulfate, etc.
  • At least one lubricant At least one lubricant.
  • the examples are, without any limitation, talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, palmitic acid, carnauba wax, mineral oil, sodium stearyl fumarate, polyethylene glycol, etc.
  • the relative amount of the tadalafil/beta-cyclodextrin co-granulate, optionally comprising auxiliary excipients as described above, in the composition is typically from about 30 to about 80 weight %, preferably from about 40 to about 60 weight %, based on the total weight of the composition.
  • the relative amount of the beta-cyclodextrin as such in the composition should not exceed 65%.
  • the composition of the present invention is advantageously formulated into a compressed dosage form, which is typically a tablet, preferably by a process of direct compression.
  • This process comprises adjusting the composition to portions - dose units - comprising dose amount of the active substance and compressing the doses of the composition to tablets on a suitable tablet press.
  • the preferred hardness of tablets is higher than 50N, advantageously higher than 75N.
  • the resulting compressed tablet for oral administration of tadalafil typically comprises a dose amount comprising from 1 to 50 mg of tadalafil, preferably 2.5, 5, 10, 20 or 40 mg of tadalafil.
  • a tablet comprises in total less than 150 mg of beta-cyclodextrin, in some embodiments the amount of beta-cyclodextrin does not exceed 75 mg.
  • the compressed dosage form preferably exhibits a dissolution rate which is characterized by a dissolution of more than 75 wt% and in some embodiments more than 80 wt% of tadalafil in 15 min when tested by a Ph.Eur. paddle method in 1000 ml of an aqueous medium containing 0.35% of SLS (sodium lauryl sulfate) with paddle rotating at a speed of 50 rpm.
  • SLS sodium lauryl sulfate
  • the tablets may be optionally further coated by a film-coat.
  • the coating serves generally for cosmetic purposes.
  • the coating material typically has no influence on the release rate, except of an inherent short initial delay in dissolution due to the time necessary to dissolve the coat.
  • the coating may be selected from amongst one or more of those suitable coating materials known in the art. Coating may be performed by applying one or more film forming polymers, with or without other pharmaceutically inert excipients, as a solution/suspension. Coating is done using any conventional coating technique known in the art, such as spray coating in a conventional coating pan or fluidized bed processor; or dip coating.
  • the co-granulate of tadalafil with beta-cyclodextrin of the present invention may be typically used in making solid pharmaceutical dosage forms, e.g., for oral administration of tadalafil.
  • the present invention provides a method of treatment, particularly that of erectile dysfunction or pulmonary arterial hypertension, comprising orally administering to a patient of need thereof a solid pharmaceutical composition comprising a therapeutical amount of co-granulate of tadalafil with beta-cyclodextrin in a molar ratio higher than 1: 1, typically a molar ratio of about 1:1.25, 1: 1.3, 1: 1.5, 1:2, 1:2.5, 1:3, advantageously in combination with a disintegrant.
  • Example 1 Co-granulate of tadalafil and beta-cyclodextrin
  • a co-granulate of tadalafil with beta-cyclodextrin of a molar ratio of 1:3 was made by the following process:
  • Example 2 Pharmaceutical tablet comprising tadalafil-beta-cyclodextrin (1:3 m/m) co-granulate
  • the co-granulate of tadalafil and beta-cyclodextrin was prepared according to the process of example 1.
  • the extragranular excipients spray-dried lactose, microcrystalline cellulose, and croscarmellose sodium were mixed with the co-granulate in a free fall blender, subsequently magnesium stearate was added and mixed with the rest of excipients.
  • the lubricated blend was compressed in an excentric press machine.
  • Comparative tablets compositions were made with a co-granulate of tadalafil/beta- cyclodextrin (1:3 molar) made of:
  • the tablet hardness was 75N in cases a], c] and d] and 100N in the case b]
  • composition comprising tadalafil-beta-cyclodextrin (1:2.5 m/m) co-granulate with an intragranular solubilizer.
  • HPMC HPMC was dissolved in water (20% w/w of the amount of cyclodextrin). This solution was mixed with cyclodextrin in a granulator for 20 minutes. Drug substance was added to the formed paste and blended for 4 h. After that, the wet mass was removed from the granulator, sieved through a conical sieve (BTS, 2.5 mm) and dried in a fluid bed at 50°C until getting a LOD ⁇ 14%. The granulate was sieved through 0.5 mm mesh (BTS) and was mixed with lactose monohydrate, microcrystalline cellulose and Na croscarmellose for 30 minutes. Magnesium stearate was added to the blend and mixed for 5 additional minutes. Finally, the lubricated blend was compressed in a rotary tablet press.
  • BTS conical sieve
  • Magnesium stearate Magnesium stearate was added to the blend and mixed for 5 additional minutes.
  • composition comprising tadalafil-beta-cyclodextrin (1:2.5 m/m) co-granulate with an extragranular solubilizer.
  • Cyclodextrin and water (20% w/w of the amount of cyclodextrin) were mixed in a high shear mixer/granulator for 20 minutes.
  • Tadalafil was added to the CD: water paste and blended for 4 h.
  • the granulate was sieved through conical sieve (BTS, 2.5 mm) and dried in fluid bed at 50°C until getting a LOD ⁇ 14%.
  • Granulate was sieved through 0.5 mm mesh (BTS).
  • TDI -CD granulate was granulated with lactose monohydrate, half of microcrystalline cellulose and 40% of the sodium croscarmellose, using water (25% w/w of granulated mass) as the granulation liquid. Nicotinamide was partially dissolved in the granulation liquid and partially added as powder in the high shear mixer. The granulated product was dried in Glatt GPCG-1. The dried granulate was blended with the remaining microcrystalline cellulose and sodium croscarmellose for 30 minutes. Finally, magnesium stearate was added and the mixture was blended for 5 minutes. The lubricated blend was compressed in a rotative press machine to get 20, 10, 5 and 2.5 mg tablets.
  • composition comprising tadalafil-beta-cyclodextrin (1:2.5 m m) co-granulate with an extragranular solubilizer.
  • Cyclodextrin and water (20% w/w of the amount of cyclodextrin) were mixed in a Mimipro high shear mixer/granulator for 20 minutes. Tadalafil was added to the
  • the tadalafil: ⁇ -CD granulate was granulated with lactose monohydrate, half of microcrystalline cellulose and 40% of the sodium croscarmellose in Mimipro. Tween was dissolved in the granulation liquid and added in the high shear mixer. The granulated product was dried in fluid bed equipment. The dried granulate was blended with the remaining microcrystalline cellulose and sodium croscarmellose for 10 minutes. Finally, magnesium stearate was added and blended for 5 minutes. The lubricated blend was compressed in a excentric press machine to get 20 mg tablets (mass 480 mg, hardness 150 N).
  • composition comprising tadalafil-beta-cyclodextrin (1:1.3 m/m) co-granulate with an intragranular solubilizer, binder and disintegrant.
  • Cyclodextrin, lactose, half of the sodium croscarmellose was mixed with an aqueous solution of PEG 4000 (amount of water is 20% w/w of the total weight of the composition) a VMA 10 high shear mixer/granulator for 20 min Tadalafil was added to the wet paste and blended for 3 hours. After blending, the granulate was dried in a fluid bed at 50°C. The dried granulate was sieved through 1.0 mm sieve.
  • the dried granulate was blended with the microcrystalline cellulose and the rest of sodium croscarmellose for 10 minutes. Finally, magnesium stearate was added and blended. The lubricated blend was compressed to get 20 mg tablets.
  • proportional tablets of 10 mg, 5 mg and 2.5 mg tadalafil were also prepared.
  • composition comprising tadalafil-beta-cyclodextrin (1:1.3 m/m) co-granulate with an intragranular solubilizer, binder and disintegrant.
  • composition comprising tadalafil-beta-cyclodextrin (1:1.3 m/m) co-granulate with an intragranular solubilizer, binder and disintegrant.
  • Cyclodextrin, lactose and half of the croscarmellose was mixed with an aqueous solution of PEG 4000 (amount of water is 20% w/w of the mass) in a VMA 10 high shear mixer/granulator for 20 minutes.
  • Tadalafil was added to the wet paste and blended for 3 hours.
  • the granulate was sieved and dried in a fluid bed at 50°C. The dried granulate was sieved through a 1.0 mm sieve.
  • the dried granulate was blended with the microcrystalline cellulose and the rest of sodium croscarmellose for 10 minutes. Finally, magnesium stearate was added and the mixture was blended. The lubricated blend was compressed in a rotative compression machine to get 20 mg. 10 mg. 5 mg and 2.5 mg tablets.
  • Cyclodextrin, lactose and half of the crospovidone was mixed with an aqueous solution of PEG 4000 (amount of water is 20% w/w of the mass) in a VMA 10 high shear mixer/granulator for 20 minutes.
  • Tadalafil was added to the wet paste and blended for 3 hours.
  • the granulate was sieved and dried in a fluid bed at 50°C.
  • the dried granulate was sieved through 1.0 mm sieve.
  • the dried granulate was blended with the microcrystalline cellulose and the rest of sodium crospovidone for 10 minutes.
  • magnesium stearate was added and blended.
  • the lubricated blend was compressed in a rotative compression machine to get 20 mg. 10 mg. 5 mg and 2.5 mg tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un produit de co-granulation de tadalafil avec de la bêta-cyclodextrine sous forme particulaire coulante, sur un procédé de fabrication de celui-ci, sur des compositions pharmaceutiques et des formes pharmaceutiques comprenant de tel produit de co-granulation et sur l'utilisation de celles-ci en médecine.
PCT/EP2012/052266 2011-02-10 2012-02-10 Composition pharmaceutique comprenant du tadalafil et une cyclodextrine Ceased WO2012107541A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
RU2013141446/15A RU2013141446A (ru) 2011-02-10 2012-02-10 Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
EP12704054.1A EP2672960A1 (fr) 2011-02-10 2012-02-10 Composition pharmaceutique comprenant du tadalafil et une cyclodextrine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2011/051969 WO2012107092A1 (fr) 2011-02-10 2011-02-10 Composition pharmaceutique comportant du tadalafil et une cyclodextrine
EPPCT/EP2011/051969 2011-02-10
EPPCT/EP2011/066730 2011-09-27
EP2011066730 2011-09-27

Publications (1)

Publication Number Publication Date
WO2012107541A1 true WO2012107541A1 (fr) 2012-08-16

Family

ID=45607248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/052266 Ceased WO2012107541A1 (fr) 2011-02-10 2012-02-10 Composition pharmaceutique comprenant du tadalafil et une cyclodextrine

Country Status (2)

Country Link
RU (1) RU2013141446A (fr)
WO (1) WO2012107541A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105213333A (zh) * 2014-06-30 2016-01-06 深圳海王药业有限公司 一种他达拉非药物组合物及其制备方法
CN106667943A (zh) * 2017-03-28 2017-05-17 南京正科医药股份有限公司 一种他达拉非片
EP3466951A1 (fr) 2014-07-23 2019-04-10 KRKA, d.d., Novo mesto Procédé de préparation d'inhibiteur de cgmp-phosphodiestérase et formulation pharmaceutique orale comprenant des co-précipités de tadalafil

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028561B1 (ru) * 2016-12-28 2017-11-30 Тева Фармасьютикал Индастриз, Лтд. Твердые лекарственные формы тадалафила

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019978A1 (fr) 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Derives tetracycliques, leurs procedes de preparation et leur utilisation
WO1996038131A1 (fr) 1995-06-02 1996-12-05 Glaxo Group Limited Procede de production d'une dispersion solide d'un medicament faiblement hydrosoluble
WO2000020033A1 (fr) 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
WO2000066099A2 (fr) 1999-04-30 2000-11-09 Lilly Icos Llc Forme de dosage unitaire
WO2001008686A1 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques a base de beta-carboline
WO2001008688A2 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc PRODUITS DE MEDICAMENTS A BASE DE β-CARBOLINE
WO2001041807A2 (fr) 1999-12-10 2001-06-14 Vivus, Inc. Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection
WO2005107810A2 (fr) * 2004-05-11 2005-11-17 Emotional Brain B.V. Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
WO2006069419A1 (fr) 2004-12-31 2006-07-06 Iceutica Pty Ltd Composition de nanoparticules et procedes de synthese de cette derniere
WO2007002125A1 (fr) 2005-06-23 2007-01-04 Schering Corporation Formulations orales à absorption rapide d'inhibiteurs de la pde5
WO2007033239A2 (fr) 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
WO2008000042A1 (fr) 2006-06-30 2008-01-03 Iceutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
WO2008005039A1 (fr) 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions solides comprenant du tadalafil et au moins un véhicule
WO2009000493A1 (fr) 2007-06-22 2008-12-31 Ratiopharm Gmbh Procédé de production d'un médicament contenant du tadalafil
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
EP2238979A1 (fr) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019978A1 (fr) 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Derives tetracycliques, leurs procedes de preparation et leur utilisation
WO1996038131A1 (fr) 1995-06-02 1996-12-05 Glaxo Group Limited Procede de production d'une dispersion solide d'un medicament faiblement hydrosoluble
WO2000020033A1 (fr) 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
WO2000066099A2 (fr) 1999-04-30 2000-11-09 Lilly Icos Llc Forme de dosage unitaire
WO2001008686A1 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques a base de beta-carboline
WO2001008688A2 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc PRODUITS DE MEDICAMENTS A BASE DE β-CARBOLINE
WO2001041807A2 (fr) 1999-12-10 2001-06-14 Vivus, Inc. Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection
WO2005107810A2 (fr) * 2004-05-11 2005-11-17 Emotional Brain B.V. Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
WO2006069419A1 (fr) 2004-12-31 2006-07-06 Iceutica Pty Ltd Composition de nanoparticules et procedes de synthese de cette derniere
WO2007002125A1 (fr) 2005-06-23 2007-01-04 Schering Corporation Formulations orales à absorption rapide d'inhibiteurs de la pde5
WO2007033239A2 (fr) 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
WO2008000042A1 (fr) 2006-06-30 2008-01-03 Iceutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
WO2008005039A1 (fr) 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions solides comprenant du tadalafil et au moins un véhicule
WO2009000493A1 (fr) 2007-06-22 2008-12-31 Ratiopharm Gmbh Procédé de production d'un médicament contenant du tadalafil
US20090047330A1 (en) * 2007-08-17 2009-02-19 Ramesh Bangalore Oral fast dissolving films for erectile dysfunction bioactive agents
EP2238979A1 (fr) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Handbook of Pharmaceutical Excipients", 2000, pages: 165 - 168
S.M. BADR-ELDIN ET AL.: "Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins, I Preparation and in vitro evaluation", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 70, 2008, pages 819 - 82 7
See also references of EP2672960A1 *
SHAIMAA M. BADR-ELDIN ET AL: "Inclusion complexes of tadalafil with natural and chemically modified [beta]-cyclodextrins. I: Preparation and in-vitro evaluation", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 70, no. 3, 1 November 2008 (2008-11-01), pages 819 - 827, XP055005612, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2008.06.024 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105213333A (zh) * 2014-06-30 2016-01-06 深圳海王药业有限公司 一种他达拉非药物组合物及其制备方法
EP3466951A1 (fr) 2014-07-23 2019-04-10 KRKA, d.d., Novo mesto Procédé de préparation d'inhibiteur de cgmp-phosphodiestérase et formulation pharmaceutique orale comprenant des co-précipités de tadalafil
CN106667943A (zh) * 2017-03-28 2017-05-17 南京正科医药股份有限公司 一种他达拉非片

Also Published As

Publication number Publication date
RU2013141446A (ru) 2015-03-20

Similar Documents

Publication Publication Date Title
JP5714492B2 (ja) 粒状体、それらの調製方法、およびそれらを含む医薬品
JP6560289B2 (ja) 新たな医薬組成物
JP2002531403A (ja) セレコキシブ組成物
JP4884975B2 (ja) 微粒子含有組成物およびその製造方法
JP2010525082A (ja) 固体投与形
CN103826616B (zh) 地瑞纳韦组合配制品
JP5569916B2 (ja) 苦味抑制製剤
JP6320371B2 (ja) エンテカビルの医薬組成物および製造方法
CN110292575B (zh) 药物组合物
JPWO2017170858A1 (ja) 溶出性に優れた経口製剤
JP2018184436A (ja) レボセチリジンを含む医薬組成物
WO2019208725A1 (fr) Composition pharmaceutique et procédé de production de composition pharmaceutique
TWI418370B (zh) 溶出安定性製劑
KR101060885B1 (ko) 염산 베니디핀 함유 의약 조성물
JP5965902B2 (ja) シロドシン−シクロデキストリン包接化合物
JP2019535696A (ja) ピリドン誘導体の医薬組成物およびその製造方法
CA2599649C (fr) Formulations medicamenteuses ayant une biodisponibilite controlee
WO2012107092A1 (fr) Composition pharmaceutique comportant du tadalafil et une cyclodextrine
WO2012107090A1 (fr) Composition de granulés comportant du tadalafil et un délitant
TW202011950A (zh) 含安定劑之醫藥品的固體製劑
JPWO2007108463A1 (ja) 溶解性が改善された固形製剤
JP2013040199A (ja) リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤
EP2672960A1 (fr) Composition pharmaceutique comprenant du tadalafil et une cyclodextrine
JP2008162955A (ja) バリン含有高密度顆粒剤
EP1729735B1 (fr) Procede de production de formes dosifiees solides comprimees adapte a des medicaments de faible solubilite aqueuse et formes dosifiees solides comprimees ainsi obtenues

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12704054

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2012704054

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012704054

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013141446

Country of ref document: RU

Kind code of ref document: A